Interestingly, both miR-150 and miR-146a are regulated by BCR-ABL1 [48,50], and miR-150 may be a useful biomarker for disease progression, where its lower expression correlates with a poor prognosis and more advanced phases of CML [44,45]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.